Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Antibiotic Use and Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma.
Journal: Head & neck
Published: May 11, 2026
Clinicogenomic Characteristics and Treatment Outcomes of Patients With Advanced ALK-Rearranged Squamous and Adenosquamous Non-Small Cell Lung Cancers.
Journal: JCO precision oncology
Published: March 30, 2026
Napsin A-specific T-cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancer.
Journal: Journal for immunotherapy of cancer
Published: June 16, 2025
Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 08, 2025
Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer.
Journal: Clinical lung cancer
Published: May 23, 2025
Update: Immunotherapeutic Strategies in HPV-Associated Head and Neck Squamous Cell Carcinoma.
Journal: Viruses
Published: April 24, 2025
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 15, 2025
Napsin A-specific T cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancer.
Journal: medRxiv : the preprint server for health sciences
Published: March 31, 2025
Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 24, 2025
Characteristics of Short-Term Survivors With ALK or ROS1-Altered Metastatic NSCLC.
Journal: JTO clinical and research reports
Published: March 21, 2025
FLAURA2: evidence for escalated first-line therapy in EGFR-mutated non-small cell lung cancer with central nervous system metastases.
Journal: Translational cancer research
Published: December 19, 2024
Last Updated: 09/26/2026